Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024)

Avalo Therapeutics filings provide 8 years of Change in Receivables readings, the most recent being -$387000.0 for Q4 2024.

  • On a quarterly basis, Change in Receivables rose 72.4% to -$387000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $475000.0, a 126.64% increase, with the full-year FY2024 number at $475000.0, up 126.64% from a year prior.
  • Change in Receivables hit -$387000.0 in Q4 2024 for Avalo Therapeutics, down from $862000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $3.7 million in Q3 2020 to a low of -$2.3 million in Q1 2022.
  • Median Change in Receivables over the past 5 years was -$145500.0 (2021), compared with a mean of -$106900.0.
  • Biggest five-year swings in Change in Receivables: skyrocketed 5501.83% in 2020 and later plummeted 5337.5% in 2023.
  • Avalo Therapeutics' Change in Receivables stood at -$2.1 million in 2020, then soared by 33.27% to -$1.4 million in 2021, then skyrocketed by 143.65% to $605000.0 in 2022, then crashed by 331.74% to -$1.4 million in 2023, then surged by 72.4% to -$387000.0 in 2024.
  • The last three reported values for Change in Receivables were -$387000.0 (Q4 2024), $862000.0 (Q3 2024), and $101000.0 (Q2 2024) per Business Quant data.